

- Surgical Sciences, Biomedical Imaging and Bioengineering Integrated Review Group
- Vaccine Research Center Board of Scientific Counselors National Institute of Allergy and Infectious Diseases
- Vascular and Hematology Integrated Review Group

5. *Justification that the information or advice provided by the Federal advisory committee or subcommittee is not available from another Federal advisory committee, another Federal Government source, or any other more cost-effective and less burdensome source:*

All members of the CCRHB are directly or indirectly associated with biomedical research, and upon acceptance of CCRHB appointment, each member is fully introduced to the unique aspects of the CC hospital which exists to provide safe delivery of patient-centric care in support of scientific research aligned with public health needs. Each year approximately 10,000 new research participants are seen at the CC as active partners in medical discovery, a partnership that has resulted in a long list of medical milestones, including the first cure of a solid tumor with chemotherapy, gene therapy, and the use of AZT to treat AIDS. The CC differs from other hospitals as it is not a general hospital, nor is it a part of a health system. There is no trauma care, no emergency room, no labor and delivery and no billing department. The mission of the CC is to provide hope through pioneering clinical research to improve human health. With our patient partners, the CC proudly is referenced as the “House of Hope.” The Board members’ recommendations are invaluable because the complex nature of the CC’s clinical research mission requires a unique balance and breadth of expertise not available at NIH or from other established sources. This advice and unique, expert perspectives cannot be obtained through other mechanisms.

6. *If the consultation is a committee renewal, a summary of the previous accomplishments of the committee and the reasons it needs to continue:*

The CCRHB is the sole entity to provide advice about hospital operations aligned with the CC’s clinical research priorities. As such, the CCRHB’s focus is on the complementary aims of achieving the highest standards of safety for research participants and the CC community, while fostering an environment of cutting-edge high-impact research to improve the health of Americans.

2016: The CCRHB recommended the submission of regular reports to the

Board addressing Patient Safety & Quality Performance Metrics. This topic became a ‘standing item’ for all Board meetings and members continue to receive a Current Executive Dashboard Report on Clinical and Safety Performance Metrics one week prior to each meeting for review. The CEO Presentation includes reference to these standing reports; and the CEO solicits discussion or questions from the Board, then reports are posted on the CC’s website for public review.

2016—Present: Annual reports to the CCRHB are delivered by the Director, Office of Research Facilities. These reports generate discussions for planned or ongoing facility changes that directly or indirectly affect CC patients, researchers, staff, and the CC community. In October 2019, all Board members signed a letter to the NIH Director, ultimately shared with Congress during budget discussions, to address needed funding for NIH maintenance issues and facility projects to improve environment of care and specialized capabilities requests, including construction of the new Surgery, Radiology and Laboratory Medicine Wing.

A key accomplishment of the CCRHB in 2022 was to provide a comprehensive review and assessment of pediatric care at the CC, focused on the delivery of care to children, current clinical research studies, and setting a vision to consider for the future of pediatric research. With the assistance of a working group that included pediatric leaders from across the country, the CCRHB provided advice that identified strengths and areas of focused improvement to be considered going forward.

7. *Explanation of why the committee/subcommittee is essential to the conduct of agency business:*

The CCRHB was created in 2016 as recommended by the Advisory Committee to the NIH Director following results of an FDA visit and review of hospital operations. Per the CCRHB charter, the purpose of the Board is to advise, consult with, and make recommendations to the NIH Principal Deputy Director (or designee) and the CEO with respect to maintaining excellence in hospital operations, safety and quality, unique clinical research care requirements for CC patients, regulatory compliance, clinical research, and hospital leadership performance oversight. Currently in its 9th year, the CCRHB has provided expert guidance and recommendations related to most aspects of CC operations.

In conclusion, this public interest determination documents that renewing the committee is in the public interest, essential to the conduct of agency business, and that the information to be obtained is not already available through another advisory committee or source within the Federal Government.

Inquiries may be directed to Patricia Brandt Hansberger, Acting Director, Office of Federal Advisory Committee Policy, Office of the Director, National Institutes of Health, 6701 Democracy Boulevard, Suite 1000, Bethesda, Maryland 20892 (Mail code 4875), Telephone (301) 496–2123, or patricia.hansberger@nih.gov.

Dated: June 3, 2026.

Denise M. Santeufemio,

Supervisory Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–11519 Filed 6–5–26; 4:15 pm]

BILLING CODE 4167–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Molecular and Structural Immunology Study Section, June 25, 2026, 09:30 a.m. to June 25, 2026, 06:00 p.m., National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 which was published in the **Federal Register** on May 21, 2026, 91 FR 29973 FR Doc No. 2026–10231.

The meeting is being amended to change the contact person from Velasco Cimica to Katie Alexander. The meeting is closed to the public.

Dated: June 5, 2026.

Bruce A. George,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–11541 Filed 6–8–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HOMELAND SECURITY

Office of the Secretary

Determination Pursuant to Section 102 of the Illegal Immigration Reform and Immigrant Responsibility Act of 1996, as Amended

AGENCY: Office of the Secretary, Department of Homeland Security.

ACTION: Notice of determination.
